

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Quarterly Period Ended **June 30, 2024**

Or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Transition Period From _____ to _____



CROSS COUNTRY HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware
*(State or other jurisdiction of
Incorporation or organization)*

0-33169
*Commission
file number*

13-4066229
*(I.R.S. Employer
Identification Number)*

6551 Park of Commerce Boulevard, N.W.
Boca Raton, Florida 33487
(Address of principal executive offices)(Zip Code)

(561) 998-2232
(Registrant's telephone number, including area code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	CCRN	The Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer Accelerated filer Non-accelerated filer
Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The registrant had outstanding 33,808,610 shares of common stock, par value \$0.0001 per share, as of July 22, 2024.

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

In addition to historical information, this Quarterly Report on Form 10-Q contains statements relating to our future results (including certain projections and business trends) that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995, and are subject to the “safe harbor” created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, “suggests”, “appears”, “seeks”, “will”, “could”, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the overall macroeconomic environment, including increased inflation and interest rates, demand for the healthcare services that we provide, both nationally and in the regions in which we operate, our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, including data privacy and protection laws, social, ethical, and security issues relating to the use of artificial intelligence, our customers’ ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors, including, without limitation, the risk factors set forth in Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (2023 Form 10-K), as filed and updated in our subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission (SEC).

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this filing. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. Except as may be required by law, the Company undertakes no obligation to update or revise forward-looking statements.

All references to “the Company”, “we”, “us”, “our”, or “Cross Country” in this Quarterly Report on Form 10-Q mean Cross Country Healthcare, Inc. and its consolidated subsidiaries.

CROSS COUNTRY HEALTHCARE, INC.

INDEX

FORM 10-Q

June 30, 2024

	PAGE
<u>PART I. – FINANCIAL INFORMATION</u>	<u>1</u>
<u>Item 1. Condensed Consolidated Financial Statements</u>	<u>1</u>
<u>Condensed Consolidated Balance Sheets (Unaudited)</u>	<u>1</u>
<u>Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited)</u>	<u>2</u>
<u>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</u>	<u>3</u>
<u>Condensed Consolidated Statements of Cash Flows (Unaudited)</u>	<u>5</u>
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	<u>6</u>
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>22</u>
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	<u>34</u>
<u>Item 4. Controls and Procedures</u>	<u>34</u>
<u>PART II. – OTHER INFORMATION</u>	<u>35</u>
<u>Item 1. Legal Proceedings</u>	<u>35</u>
<u>Item 1A. Risk Factors</u>	<u>35</u>
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>35</u>
<u>Item 5. Other Information</u>	<u>36</u>
<u>Item 6. Exhibits</u>	<u>37</u>
<u>Signatures</u>	<u>38</u>

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

**CROSS COUNTRY HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands)**

	June 30, 2024	December 31, 2023
Assets		
Current assets:		
Cash and cash equivalents	\$ 69,601	\$ 17,094
Accounts receivable, net of allowances of \$35,744 in 2024 and \$20,547 in 2023	242,333	372,352
Income taxes receivable	8,967	6,898
Prepaid expenses	6,248	7,681
Insurance recovery receivable	8,796	9,097
Other current assets	1,813	2,031
Total current assets	337,758	415,153
Property and equipment, net of accumulated depreciation of \$18,859 in 2024 and \$15,808 in 2023	29,033	27,339
Operating lease right-of-use assets	2,635	2,599
Goodwill	135,430	135,430
Other intangible assets, net	49,016	54,468
Deferred tax assets	10,064	5,954
Insurance recovery receivable	23,332	25,714
Cloud computing	8,916	5,987
Other assets	6,699	6,673
Total assets	\$ 602,883	\$ 679,317
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued expenses	\$ 55,682	\$ 85,333
Accrued compensation and benefits	46,609	52,297
Operating lease liabilities	2,085	2,604
Earnout liability	4,100	6,794
Other current liabilities	1,639	1,559
Total current liabilities	110,115	148,587
Operating lease liabilities	2,652	2,663
Accrued claims	35,614	34,853
Earnout liability	—	5,000
Uncertain tax positions	11,642	10,603
Other liabilities	3,798	4,218
Total liabilities	163,821	205,924
Commitments and contingencies		
Stockholders' equity:		
Common stock	3	4
Additional paid-in capital	215,449	236,417
Accumulated other comprehensive loss	(1,389)	(1,385)
Retained earnings	224,999	238,357
Total stockholders' equity	439,062	473,393
Total liabilities and stockholders' equity	\$ 602,883	\$ 679,317

See accompanying notes to the condensed consolidated financial statements

CROSS COUNTRY HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(Unaudited, amounts in thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Revenue from services	\$ 339,771	\$ 540,695	\$ 718,945	\$ 1,163,402
Operating expenses:				
Direct operating expenses	268,966	417,556	570,843	900,840
Selling, general and administrative expenses	60,258	78,938	123,510	163,198
Credit loss expense	18,858	3,134	20,148	8,042
Depreciation and amortization	4,719	4,432	9,361	9,336
Restructuring costs	2,116	913	3,054	1,342
Legal and other losses	3,946	—	7,596	1,125
Impairment charges	114	533	718	533
Total operating expenses	358,977	505,506	735,230	1,084,416
(Loss) income from operations	(19,206)	35,189	(16,285)	78,986
Other expenses (income):				
Interest expense	568	3,149	1,030	6,839
Loss on early extinguishment of debt	—	1,723	—	1,723
Other (income) expense, net	(212)	11	(1,442)	(1)
(Loss) income before income taxes	(19,562)	30,306	(15,873)	70,425
Income tax (benefit) expense	(3,512)	8,961	(2,515)	19,644
Net (loss) income attributable to common stockholders	\$ (16,050)	\$ 21,345	\$ (13,358)	\$ 50,781
Other comprehensive (loss) income:				
Unrealized foreign currency translation (loss) gain, net of tax	(1)	1	(4)	8
Comprehensive (loss) income	\$ (16,051)	\$ 21,346	\$ (13,362)	\$ 50,789
Net (loss) income per share attributable to common stockholders - Basic	\$ (0.47)	\$ 0.60	\$ (0.39)	\$ 1.43
Net (loss) income per share attributable to common stockholders - Diluted	\$ (0.47)	\$ 0.60	\$ (0.39)	\$ 1.41
Weighted average common shares outstanding:				
Basic	33,960	35,351	34,088	35,606
Diluted	33,960	35,524	34,088	36,041

See accompanying notes to the condensed consolidated financial statements

CROSS COUNTRY HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Three Months Ended June 30, 2024 and 2023
(Unaudited, amounts in thousands)

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss, net	Retained Earnings	Stockholders' Equity
	Shares	Dollars				
Balances at March 31, 2024	34,326	\$ 4	\$ 228,525	\$ (1,388)	\$ 241,049	\$ 468,190
Vesting of restricted stock	42	—	(247)	—	—	(247)
Equity compensation	—	—	2,259	—	—	2,259
Stock repurchase and retirement	(980)	(1)	(14,945)	—	—	(14,946)
Stock repurchase excise tax	—	—	(143)	—	—	(143)
Foreign currency translation adjustment, net of taxes	—	—	—	(1)	—	(1)
Net loss	—	—	—	—	(16,050)	(16,050)
Balances at June 30, 2024	33,388	\$ 3	\$ 215,449	\$ (1,389)	\$ 224,999	\$ 439,062

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss, net	Retained Earnings	Stockholders' Equity
	Shares	Dollars				
Balances at March 31, 2023	35,454	\$ 4	\$ 258,144	\$ (1,380)	\$ 195,162	\$ 451,930
Vesting of restricted stock	49	—	(373)	—	—	(373)
Equity compensation	—	—	2,205	—	—	2,205
Stock repurchase and retirement	(198)	—	(4,723)	—	—	(4,723)
Stock repurchase excise tax	—	—	(37)	—	—	(37)
Foreign currency translation adjustment, net of taxes	—	—	—	1	—	1
Net income	—	—	—	—	21,345	21,345
Balances at June 30, 2023	35,305	\$ 4	\$ 255,216	\$ (1,379)	\$ 216,507	\$ 470,348

See accompanying notes to the condensed consolidated financial statements

CROSS COUNTRY HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Six Months Ended June 30, 2024 and 2023
(Unaudited, amounts in thousands)

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss, net	Retained Earnings	Stockholders' Equity
	Shares	Dollars				
Balances at December 31, 2023	34,385	\$ 4	\$ 236,417	\$ (1,385)	\$ 238,357	\$ 473,393
Vesting of restricted stock	293	—	(2,953)	—	—	(2,953)
Equity compensation	—	—	3,457	—	—	3,457
Stock repurchase and retirement	(1,290)	(1)	(21,313)	—	—	(21,314)
Stock repurchase excise tax	—	—	(159)	—	—	(159)
Foreign currency translation adjustment, net of taxes	—	—	—	(4)	—	(4)
Net loss	—	—	—	—	(13,358)	(13,358)
Balances at June 30, 2024	33,388	\$ 3	\$ 215,449	\$ (1,389)	\$ 224,999	\$ 439,062

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss, net	(Accumulated Deficit) Retained Earnings	Stockholders' Equity
	Shares	Dollars				
Balances at December 31, 2022	36,303	\$ 4	\$ 292,876	\$ (1,387)	\$ 165,726	\$ 457,219
Vesting of restricted stock	424	—	(4,886)	—	—	(4,886)
Equity compensation	—	—	3,980	—	—	3,980
Stock repurchase and retirement	(1,422)	—	(36,483)	—	—	(36,483)
Stock repurchase excise tax	—	—	(271)	—	—	(271)
Foreign currency translation adjustment, net of taxes	—	—	—	8	—	8
Net income	—	—	—	—	50,781	50,781
Balances at June 30, 2023	35,305	\$ 4	\$ 255,216	\$ (1,379)	\$ 216,507	\$ 470,348

See accompanying notes to the condensed consolidated financial statements

CROSS COUNTRY HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)

	Six Months Ended June 30,	
	2024	2023
Cash flows from operating activities		
Consolidated net (loss) income	\$ (13,358)	\$ 50,781
Adjustments to reconcile net (loss) income to net cash provided by operating activities:		
Depreciation and amortization	9,361	9,336
Provision for allowances	20,084	9,807
Deferred income tax benefit	(4,034)	(490)
Non-cash lease expense	474	535
Impairment charges	718	533
Loss on early extinguishment of debt	—	1,723
Equity compensation	3,457	3,980
Other non-cash costs	405	658
Changes in operating assets and liabilities:		
Accounts receivable	109,935	146,443
Prepaid expenses and other assets	(1,076)	3,372
Income taxes	(1,033)	8,337
Accounts payable and accrued expenses	(33,259)	(66,548)
Operating lease liabilities	(1,576)	(2,153)
Other	(1,686)	(201)
Net cash provided by operating activities	<u>88,412</u>	<u>166,113</u>
Cash flows from investing activities		
Purchases of property and equipment	(5,059)	(7,674)
Acquisition-related settlements	—	182
Net cash used in investing activities	<u>(5,059)</u>	<u>(7,492)</u>
Cash flows from financing activities		
Principal payments on term loan	—	(73,875)
Borrowings under Senior Secured Asset-Based revolving credit facility	17,319	553,419
Repayments on Senior Secured Asset-Based revolving credit facility	(17,319)	(599,219)
Cash paid for shares withheld for taxes	(2,954)	(4,886)
Stock repurchase and retirement	(21,313)	(36,483)
Payment of contingent consideration	(6,579)	—
Other	—	(508)
Net cash used in financing activities	<u>(30,846)</u>	<u>(161,552)</u>
Effect of exchange rate changes on cash	—	—
Change in cash and cash equivalents	52,507	(2,931)
Cash and cash equivalents at beginning of period	17,094	3,604
Cash and cash equivalents at end of period	<u>\$ 69,601</u>	<u>\$ 673</u>

See accompanying notes to the condensed consolidated financial statements

CROSS COUNTRY HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

1. ORGANIZATION AND BASIS OF PRESENTATION

Nature of Business

The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.

The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the 2023 Form 10-K. The December 31, 2023 condensed consolidated balance sheet included herein was derived from the December 31, 2023 audited consolidated balance sheet included in the 2023 Form 10-K.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers' compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates.

Risks and Uncertainties

The Company's future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in the 2023 Form 10-K.

Accounts Receivable, net

The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for credit losses and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors' time worked but not yet billed at June 30, 2024 and December 31, 2023 totaled \$59.2 million and \$89.9 million, respectively.

The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for credit losses is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for credit losses when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of

its accounts receivable based on a combination of factors. The Company bases its allowance for credit losses estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic conditions when estimating its allowance for credit losses.

The opening balance of the allowance for credit losses is reconciled to the closing balance for expected credit losses as follows:

	2024	2023
	(amounts in thousands)	
Balance at January 1	\$ 19,640	\$ 13,058
Credit Loss Expense	1,290	4,908
Write-Offs, net of Recoveries	(1,555)	54
Balance at March 31	19,375	18,020
Credit Loss Expense	18,858	3,134
Write-Offs, net of Recoveries	(3,201)	(4,240)
Balance at June 30	<u>\$ 35,032</u>	<u>\$ 16,914</u>

In addition to the allowance for credit losses, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The sales allowance balance as of June 30, 2024 and December 31, 2023 was \$0.7 million and \$0.9 million, respectively.

The Company's contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are healthcare systems with a significant percentage in acute-care facilities. No single customer accounted for more than 10% of the Company's revenue for the three and six months ended June 30, 2024 and 2023, or the Company's accounts receivable balance as of June 30, 2024 and December 31, 2023. In 2023, there was an increase in credit loss expense primarily driven by a deterioration in the accounts receivable aging stemming from a single managed service programs (MSP) customer. On May 6, 2024, the customer filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code. As a result, the Company recorded an associated credit loss expense of \$19.4 million in the second quarter of 2024.

Restructuring Costs

The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations and comprehensive (loss) income primarily include employee termination costs and lease-related exit costs.

Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:

	Employee Termination Costs	Lease-Related Exit Costs
	(amounts in thousands)	
Balance at January 1, 2024	\$ 895	\$ 1,184
Charged to restructuring	188	525
Payments	(759)	(218)
Balance at March 31, 2024	324	1,491
Charged to restructuring	1,740	—
Payments	(1,787)	(254)
Balance at June 30, 2024	<u>\$ 277</u>	<u>\$ 1,237</u>

Recent Accounting Pronouncements

On December 14, 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires that public business entities, on an annual basis, (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The amendments also require that all entities disclose, on an annual basis, disaggregated information regarding income taxes paid and income tax expense. This guidance is effective for annual periods beginning after December 15, 2024. The amendments should be applied prospectively, but retrospective application is permitted. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company expects to adopt this standard for its annual report for the fiscal year ended December 31, 2025. The Company expects this ASU to only impact its disclosures with no impacts to results of operations, cash flows, and financial condition.

On November 27, 2023, the FASB issued ASU No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and requires certain disclosures related to the chief operating decision maker. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company expects to adopt this standard for its fiscal year ended December 31, 2024. The Company expects this ASU to only expand its disclosures with no impacts to results of operations, cash flows, and financial condition.

3. REVENUE RECOGNITION

The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.

Three Months ended June 30, 2024			
	Nurse And Allied Staffing	Physician Staffing	Total Segments
	(amounts in thousands)		
Temporary Staffing Services	\$ 282,501	\$ 45,836	\$ 328,337
Other Services	8,950	2,484	11,434
Total	\$ 291,451	\$ 48,320	\$ 339,771

Three Months ended June 30, 2023			
	Nurse And Allied Staffing	Physician Staffing	Total Segments
	(amounts in thousands)		
Temporary Staffing Services	\$ 483,560	\$ 43,115	\$ 526,675
Other Services	11,816	2,204	14,020
Total	\$ 495,376	\$ 45,319	\$ 540,695

Six Months ended June 30, 2024			
	Nurse And Allied Staffing	Physician Staffing	Total Segments
	(amounts in thousands)		
Temporary Staffing Services	\$ 607,475	\$ 90,325	\$ 697,800
Other Services	16,162	4,983	21,145
Total	\$ 623,637	\$ 95,308	\$ 718,945

Six Months ended June 30, 2023			
	Nurse And Allied Staffing	Physician Staffing	Total Segments
Temporary Staffing Services	\$ 1,051,210	\$ 81,312	\$ 1,132,522
Other Services	26,468	4,412	30,880
Total	\$ 1,077,678	\$ 85,724	\$ 1,163,402

See Note 12 - Segment Data.

4. ACQUISITIONS

HireUp

On December 13, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of HireUp Leadership Inc. (HireUp) for a purchase price of \$6.0 million in cash, subject to adjustment, and \$0.8 million in shares (or 29,811 shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes.

The sellers were eligible to receive up to an additional \$8.0 million in earnout cash consideration based on HireUp's revenues and Adjusted EBITDA for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. Quarterly throughout 2023, and during the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023. The Company paid the remaining earnout liability of \$1.7 million in the first quarter of 2024. See Note 10 - Fair Value Measurements.

Mint

On October 3, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC (collectively, Mint) for a purchase price of \$27.0 million in cash, subject to adjustment, and \$3.6 million in shares (or 114,278 shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes.

The sellers were eligible to receive up to an additional \$10.0 million in earnout cash consideration based on Mint's revenues and gross profit for each of the twelve-month periods ending on the first and second anniversaries of the first day of the calendar month following the closing date. In the fourth quarter of 2023, the Company performed a calculation for the first measurement period, resulting in the achievement of a \$4.9 million earnout, which was paid in the first quarter of 2024. During the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout for the second measurement period would only be partially achieved and, as a result, recognized a decrease in the fair value of the related liabilities. The remaining liability of \$4.1 million is included in the current portion of earnout liability on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements.

Cross Country Workforce Solutions Group (CCWSG)

On June 8, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Workforce Solutions Group, Inc. (WSG) for a purchase price of \$25.0 million in cash and \$5.0 million in shares (or 307,730 shares) of the Company's common stock.

The sellers were eligible to receive an earnout based on the business' performance through three years after the acquisition date that could provide up to an additional \$15.0 million in cash. In the third quarter of 2022, the Company determined that the contingent consideration earnout was achieved for the 2021 through 2022 period and, as a result, the Company made a \$7.5 million earnout payment. In the third quarter of 2023, the Company determined that the contingent consideration earnout was achieved for the 2022 through 2023 period and, as a result, the Company made the final \$7.5 million earnout payment.

5. COMPREHENSIVE (LOSS) INCOME

Total comprehensive (loss) income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations and comprehensive (loss) income. Certain of the Company's foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of \$1.5 million as of June 30, 2024 and December 31, 2023.

The income tax impact related to components of other comprehensive (loss) income for the three and six months ended June 30, 2024 and 2023 is included in unrealized foreign currency translation (loss) gain, net of tax in the condensed consolidated statements of operations and comprehensive (loss) income.

6. EARNINGS PER SHARE

The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2024	2023	2024	2023
	(amounts in thousands, except per share data)			
Numerator:				
Net (loss) income attributable to common stockholders - Basic and Diluted	\$ (16,050)	\$ 21,345	\$ (13,358)	\$ 50,781
Denominator:				
Weighted average common shares - Basic	33,960	35,351	34,088	35,606
Effect of diluted shares:				
Share-based awards	—	173	—	435
Weighted average common shares - Diluted ^a	33,960	35,524	34,088	36,041
Net (loss) income per share attributable to common stockholders - Basic	\$ (0.47)	\$ 0.60	\$ (0.39)	\$ 1.43
Net (loss) income per share attributable to common stockholders - Diluted	\$ (0.47)	\$ 0.60	\$ (0.39)	\$ 1.41

(a) For the three and six months ended June 30, 2024, the effect of diluted shares was not included in the weighted average share calculation due to the Company's net operating loss position.

The following table represents the share-based awards that could potentially dilute net (loss) income per share attributable to common stockholders in the future that were not included in the computation of diluted net (loss) income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented.

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2024	2023	2024	2023
	(amounts in thousands)			
Share-based awards	507	—	256	—

7. GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS

The Company had the following acquired intangible assets:

	June 30, 2024			December 31, 2023		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
(amounts in thousands)						
Intangible assets subject to amortization:						
Databases	\$ 39,430	\$ 21,253	\$ 18,177	\$ 45,930	\$ 24,971	\$ 20,959
Customer relationships	52,538	28,561	23,977	52,538	26,286	26,252
Trade names	900	773	127	900	548	352
Software	1,700	865	835	1,700	695	1,005
Other intangible assets, net	\$ 94,568	\$ 51,452	\$ 43,116	\$ 101,068	\$ 52,500	\$ 48,568
Intangible assets not subject to amortization:						
Trade names, indefinite-lived			\$ 5,900			\$ 5,900

As of June 30, 2024, estimated annual amortization expense was as follows:

	(amounts in thousands)	
Years Ending December 31:		
2024	\$	5,030
2025		9,571
2026		8,362
2027		6,191
2028		4,791
Thereafter		9,171
	\$	<u>43,116</u>

Goodwill, Trade Names, and Other Intangible Assets Impairment

The Company tests reporting units' goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances, such as reporting units' historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors, and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed.

As of June 30, 2024, the Company performed a qualitative assessment of each of its reporting units and determined that it was not more likely than not that the fair value of its reporting units dropped below their carrying value. Although management believes that the Company's current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, there can be no assurance that the estimates and assumptions management used for purposes of its assessment as of June 30, 2024 will prove to be accurate predictions of future performance.

As of June 30, 2024, goodwill by reporting segment was: \$112.5 million for Nurse and Allied Staffing and \$22.9 million for Physician Staffing, for a total of \$135.4 million.

For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of June 30, 2024, the Company performed a qualitative assessment of its trade names and other intangible assets and determined it was not more likely than not that their carrying value may not be recoverable. During the three months ended June 30, 2023, the Company wrote off an abandoned IT project, resulting in an impairment charge.

8. DEBT

The Company's debt consists of the following:

	June 30, 2024		December 31, 2023	
	Principal	Debt Issuance Costs	Principal	Debt Issuance Costs
	(amounts in thousands)			
Senior Secured Asset-Based Loan, interest of 7.19% and 6.99% at June 30, 2024 and December 31, 2023, respectively	\$ —	\$ (2,217)	\$ —	\$ (2,623)
Debt	\$ —	\$ (2,217)	\$ —	\$ (2,623)

As of June 30, 2024 and December 31, 2023, there was no debt outstanding on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its senior secured asset-based credit facility as an asset, included in other assets on the condensed consolidated balance sheets.

2021 Term Loan Credit Agreement

On June 8, 2021, the Company entered into a Term Loan Credit Agreement (Term Loan Agreement) with certain lenders identified therein (collectively, the Lenders) and Wilmington Trust, National Association as administrative agent and collateral agent, pursuant to which the Lenders extended to the Company a six-year second lien subordinated term loan in the amount of \$100.0 million (term loan).

On November 18, 2021, the Company amended the Term Loan Agreement (Term Loan First Amendment), which provided the Company an incremental borrowing in an aggregate amount equal to \$75.0 million. Additionally, the Term Loan First Amendment increased the aggregate amount of all increases (as defined in the Term Loan Agreement) to be no greater than \$115.0 million.

On April 14, 2023, the Company amended the Term Loan Agreement (Term Loan Second Amendment), which provided the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or the Base Rate (as defined in the Term Loan Agreement), at the election of the borrowers, plus an applicable margin.

On June 30, 2023, the Company repaid all outstanding obligations of \$73.9 million under the term loan and terminated the Term Loan Agreement. As a result, debt issuance costs of \$1.7 million were written off in the second quarter of 2023. There were no prepayment premiums associated with the payoff and all subsidiary guarantees of the term loan were automatically released.

2019 Asset-Based Loan Agreement

Effective October 25, 2019, the Company terminated its prior senior credit facility and entered into an asset-based loan agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo Bank, N.A., and PNC Bank N.A., as well as other Lenders (as defined therein) from time to time parties thereto (Loan Agreement). The Loan Agreement provided for a five-year revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to \$120.0 million, including a sublimit for swing loans up to \$15.0 million and a \$35.0 million sublimit for standby letters of credit.

On June 30, 2020, the Company amended the Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from \$120.0 million to \$130.0 million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same.

On March 8, 2021, the Company amended the Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from \$130.0 million to \$150.0 million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers.

On June 8, 2021, the Company amended the Loan Agreement (Third Amendment), which permitted the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement (as defined in the Loan Agreement), and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars.

On November 18, 2021, the Company amended the Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to \$175.0 million.

On March 21, 2022, the Company amended the Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from \$150.0 million to \$300.0 million, extended the term of the credit facility for an additional five years, through March 21, 2027, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the SOFR or the Base Rate (as defined in the Loan Agreement), at the election of the borrowers, plus an applicable margin. The applicable margin increased 10 basis points due to the credit spread associated with the transition to SOFR.

On September 29, 2023, the Company amended the Loan Agreement (Sixth Amendment), which changed the minimum fixed charge coverage ratio from a maintenance covenant to a springing covenant based on excess availability, which provides for compliance with the covenant only during a compliance period (any time that excess availability falls below a certain threshold), and in such case, the financial covenant shall be tested during this period.

These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and are amortized ratably over the remaining term of the Loan Agreement.

The ABL availability is subject to a borrowing base of up to 85% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. At June 30, 2024, there were no borrowings drawn under the ABL, and borrowing base availability under the ABL was \$166.7 million, with \$152.9 million of availability net of \$13.8 million of letters of credit outstanding related to workers' compensation and professional liability policies.

As of June 30, 2024, the interest rate spreads and fees under the ABL were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate margin would have been 0.75% for the revolving portion. The SOFR and Base Rate margins are subject to monthly adjustments, pursuant to a pricing matrix based on the Company's excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is 0.375% of the average daily unused portion of the revolving credit facility.

The Loan Agreement contains various restrictions applicable to the Company and its subsidiaries. For the three months ended June 30, 2024, the excess availability did not fall below the stated threshold and, as a result, there was no covenant compliance period. Obligations under the ABL are secured by substantially all of the assets of the borrowers and guarantors, subject to customary exceptions.

9. LEASES

The Company's lease population of its right-of-use assets and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent months during the lease term and/or escalating rent payments and, particularly for the Company's longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions.

As a part of the Company's restructuring activities, management periodically reduces or fully vacates leased office space, which results in right-of-use impairment charges. The Company may also write off leasehold improvements or other property and equipment related to these locations. The measurement of these impairments is a Level 3 fair value measurement. For the three and six months ended June 30, 2024 and 2023, the Company did not record any material lease-related impairment charges. See Note 2 - Summary of Significant Accounting Policies for a description of the Company's restructuring activities.

The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:

Classification on Condensed Consolidated Balance Sheets:	June 30, 2024		December 31, 2023	
	(amounts in thousands)			
Operating lease right-of-use assets	\$	2,635	\$	2,599
Operating lease liabilities - current	\$	2,085	\$	2,604
Operating lease liabilities - non-current	\$	2,652	\$	2,663
		June 30, 2024		December 31, 2023
Weighted average remaining lease term		3.06 years		2.2 years
Weighted average discount rate		6.78 %		6.36 %

The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of June 30, 2024:

		(amounts in thousands)	
Years Ending December 31:			
2024		\$	1,133
2025			2,372
2026			652
2027			533
2028			450
Thereafter			113
Total minimum lease payments			5,253
Less: amount of lease payments representing interest			(516)
Present value of future minimum lease payments			4,737
Less: operating lease liabilities - current			(2,085)
Operating lease liabilities - non-current		\$	2,652

Other Information

The table below provides information regarding supplemental cash flows:

	Six Months Ended	
	June 30,	
	2024	2023
	(amounts in thousands)	
Supplemental Cash Flow Information:		
Cash paid for amounts included in the measurement of operating lease liabilities	\$ 1,734	\$ 2,434
Right-of-use assets acquired under operating lease	\$ 1,047	\$ 88

The components of lease expense are as follows:

	Three Months Ended	
	June 30,	
	2024	2023
	(amounts in thousands)	
Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income:		
Operating lease expense	\$ 363	\$ 412
Short-term lease expense	\$ 358	\$ 738
Variable and other lease costs	\$ (45)	\$ 275

	Six Months Ended	
	June 30,	
	2024	2023
	(amounts in thousands)	
Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income:		
Operating lease expense	\$ 686	\$ 904
Short-term lease expense	\$ 777	\$ 1,818
Variable and other lease costs	\$ 580	\$ 273

Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations and comprehensive (loss) income, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material.

As of June 30, 2024, the Company did not have any material operating leases that had not yet commenced, and does not have any finance lease contracts.

10. FAIR VALUE MEASUREMENTS

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Items Measured at Fair Value on a Recurring Basis:

The Company’s financial assets/liabilities required to be measured on a recurring basis were primarily its: (i) deferred compensation asset included in other assets; and (ii) deferred compensation liability included in other liabilities on its condensed consolidated balance sheets.

Deferred compensation—The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company’s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents.

The estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis is as follows:

	Fair Value Measurements	
	June 30, 2024	December 31, 2023
	(amounts in thousands)	
Financial Assets:		
(Level 1)		
Deferred compensation asset	\$ 3,561	\$ 3,298
Financial Liabilities:		
(Level 1)		
Deferred compensation liability	\$ 2,899	\$ 3,343

Items Measured at Fair Value on a Non-Recurring Basis:

The Company’s non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

The Company did not record any material impairment charges during the three and six months ended June 30, 2024 and 2023.

Other Fair Value Disclosures:

Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and accrued expenses approximate their carrying amount due to the short-term nature of these instruments.

Other financial instruments measured or recorded at fair value include earnout liabilities related to the (i) Mint and (ii) HireUp acquisitions, as discussed below.

(i) Potential earnout payments related to the Mint acquisition are contingent upon meeting certain performance requirements based on 2022 through 2024 performance. On a quarterly basis, the Company performs an analysis using multiple forecasted scenarios to determine the fair value of the earnout liability. In the fourth quarter of 2023, the Company performed the earnout calculation for the first measurement period, resulting in an earnout of \$4.9 million, which was paid in the first quarter of 2024. During the first quarter of 2024, the Company determined that the earnout for the second measurement period would only be partially achieved and, as a result, recognized a decrease in the fair value of the related liabilities. The remaining liability of \$4.1 million is included in the current portion of earnout liability on the condensed consolidated balance sheets. The carrying amount of the earnout liability approximates fair value. See Note 4 - Acquisitions.

(ii) Potential earnout payments related to the HireUp acquisition were contingent upon meeting certain performance requirements based on 2022 through 2024 performance. Quarterly throughout 2023 and in the first quarter of 2024, the Company performed analyses using multiple updated forecasted scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities in the second and third quarters of 2023 and the first quarter of 2024. The remaining liability of \$1.7 million was paid in the first quarter of 2024. See Note 4 - Acquisitions.

Concentration of Credit Risk:

See discussion of credit losses and allowance for credit losses in Note 2 - Summary of Significant Accounting Policies. Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes that the concentration of credit risk is limited.

11. STOCKHOLDERS' EQUITY

Stock Repurchase Program

On May 1, 2023, the Company's Board of Directors authorized approximately \$59.0 million in additional share repurchases to be added to the prior authorized repurchase program, such that, effective for trades made after May 3, 2023, the aggregate amount available for stock repurchases was set at \$100.0 million (the Repurchase Program). The shares can be repurchased from time-to-time in the open market or in privately negotiated transactions. The Repurchase Program does not obligate the Company to repurchase any particular number of shares of common stock and may be discontinued by the Board of Directors at any time. Decisions regarding the amount and the timing of repurchases under the Repurchase Program will be subject to the Company's available liquidity and cash on hand, applicable legal requirements, the terms of the Company's Loan Agreement, general market conditions, and other factors.

During the fourth quarter of 2022, the Company entered into a Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company's blackout periods, effective through November 2, 2023. During the third quarter of 2023, the Company entered into a new Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company's blackout periods, beginning on January 2, 2024 and effective through November 7, 2024.

During the three months ended June 30, 2024, the Company repurchased a total of 979,921 shares of common stock for \$14.9 million, at an average price of \$15.23 per share. During the six months ended June 30, 2024, the Company repurchased a total of 1,290,156 shares of common stock for an aggregate of \$21.3 million, at an average price of \$16.50 per share. During the three months ended June 30, 2023, the Company repurchased a total of 198,463 shares of common stock for \$4.7 million, at an average price of \$23.78 per share. During the six months ended June 30, 2023, the Company repurchased a total of 1,421,867 shares of common stock for \$36.5 million, at an average price of \$25.64 per share.

As of June 30, 2024, the Company had \$56.0 million remaining for share repurchase under the Repurchase Program, subject to certain conditions in the Company's Loan Agreement. As of June 30, 2024, the Company had 33,388,000 unrestricted shares of common stock outstanding.

Share-Based Payments

On May 14, 2024, the Company's stockholders approved the Cross Country Healthcare, Inc. 2024 Omnibus Incentive Plan (2024 Plan). Pursuant to the 2024 Plan, awards may be granted to employees, non-employee directors, consultants, and key advisors of the Company and its subsidiaries, including stock options (including incentive stock options and nonqualified stock options), stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards. The 2024 Plan was adopted principally to serve as a successor plan to the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan) and to increase the number of shares of Company common stock reserved for equity-based awards to 2,400,000 shares (in addition to the share reserve amount that remained available under the 2020 Plan immediately prior to the adoption of the 2024 Plan and other eligible returning shares). No awards may be granted under the 2024 Plan after May 13, 2034.

The following table summarizes restricted stock awards and performance stock awards activity issued under the 2020 Plan and the 2024 Plan (Plans) for the six months ended June 30, 2024:

	Restricted Stock Awards		Performance Stock Awards	
	Number of Shares	Weighted Average Grant Date Fair Value	Number of Target Shares	Weighted Average Grant Date Fair Value
Unvested restricted stock awards, January 1, 2024	547,534	\$ 20.42	417,197	\$ 18.75
Granted	375,377	\$ 18.05	170,880	\$ 18.67
Vested	(308,241)	\$ 19.02	(145,908)	\$ 12.71
Forfeited	(50,256)	\$ 20.81	(23,875)	\$ 21.39
Unvested restricted stock awards, June 30, 2024	564,414	\$ 19.58	418,294	\$ 20.68

Restricted stock awards granted under the Company's Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company's common stock. Share-based compensation expense is measured by the market value of the Company's stock on the date of grant.

Awards granted to non-employee directors under the Plans will vest on the first anniversary of such grant date, or earlier subject to retirement eligibility. In addition, effective for the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires.

Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2024, the Company's Compensation Committee of the Board of Directors approved a 101% level of attainment for the 2021 performance-based share awards, resulting in the issuance of 145,908 performance shares that vested on March 31, 2024.

During the three and six months ended June 30, 2024, \$2.3 million and \$3.5 million, respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 42,227 and 293,251 shares, respectively, of common stock were issued upon the vesting of restricted and performance stock.

During the three and six months ended June 30, 2023, \$2.2 million and \$4.0 million, respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 49,582 and 424,274 shares, respectively, of common stock were issued upon the vesting of restricted and performance stock.

12. SEGMENT DATA

The Company's segments offer services to its customers as described below:

- Nurse and Allied Staffing** – Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, physician, human resources, and finance, MSP services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides executive search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services, and offers the Company's SaaS-based, proprietary, vendor management technology, Intellify® to facilities to manage all or a portion of their agency services. Its customers include: public and private acute care hospitals, non-acute care hospitals, government facilities, local healthcare plans, national healthcare plans, managed care providers, public schools, charter schools, academic medical centers, Programs of All-Inclusive Care for the Elderly (PACE) programs, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States.
- Physician Staffing** – Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.

The Company evaluates performance of each segment primarily based on revenue and contribution income. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments' internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to or among the operating segments.

Information on operating segments and a reconciliation to (loss) income from operations for the periods indicated are as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
	(amounts in thousands)			
Revenue from services:				
Nurse and Allied Staffing	\$ 291,451	\$ 495,376	\$ 623,637	\$ 1,077,678
Physician Staffing	48,320	45,319	95,308	85,724
	<u>\$ 339,771</u>	<u>\$ 540,695</u>	<u>\$ 718,945</u>	<u>\$ 1,163,402</u>
Contribution income:				
Nurse and Allied Staffing	\$ 5,820	\$ 56,481	\$ 33,003	\$ 123,650
Physician Staffing	4,033	3,541	7,171	5,265
	<u>9,853</u>	<u>60,022</u>	<u>40,174</u>	<u>128,915</u>
Corporate overhead ^(a)	18,161	18,891	35,727	37,547
Depreciation and amortization	4,719	4,432	9,361	9,336
Restructuring costs	2,116	913	3,054	1,342
Legal and other losses	3,946	—	7,596	1,125
Impairment charges	114	533	718	533
Other costs ^(b)	3	64	3	46
(Loss) income from operations	<u>\$ (19,206)</u>	<u>\$ 35,189</u>	<u>\$ (16,285)</u>	<u>\$ 78,986</u>

(a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).

(b) Other costs include acquisition and integration-related costs.

13. CONTINGENCIES

Legal Proceedings

From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These proceedings primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company's current assessments, including available insurance recoveries, which would impact the Company's profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company's financial results. During the second quarter of 2024, the Company

recorded legal settlement charges related to the resolution of a class action settlement agreement, as well as costs related to an unrecoverable asset. The Company believes that the outcome of any outstanding loss contingencies as of June 30, 2024 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows.

Sales and Other State Non-Income Tax Liabilities

The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses in the Company's condensed consolidated statements of operations and comprehensive (loss) income and the liability is reflected in sales tax payable within other current liabilities in its condensed consolidated balance sheets.

14. INCOME TAXES

The Company has historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the Annual Effective Tax Rate (AETR) for the full fiscal year to ordinary income for the reporting period. For the three and six months ended June 30, 2024, the Company used actual results to calculate the provision for income taxes. It determined that since small changes in estimated ordinary income would result in significant changes in the estimated AETR, the historical method would not provide a reliable estimate for the three and six month periods ended June 30, 2024.

The Company's effective tax rate was 18.0% and 15.8% for the three and six months ended June 30, 2024, respectively, and 29.6% and 27.9% for the three and six months ended June 30, 2023, respectively. In addition to using actual results, a book loss primarily driven by credit loss expense as discussed in Note 2 - Summary of Significant Accounting Policies, relative to nondeductible items, caused the quarterly and year-to-date effective tax rates to be significantly different from the historical annual effective tax rate.

As of June 30, 2024, the Company had approximately \$11.6 million of unrecognized tax benefits included in other non-current liabilities, \$11.0 million, net of deferred taxes, which would impact the effective tax rate if recognized. During the six months ended June 30, 2024, the Company had net increases of \$1.0 million to its current year unrecognized tax benefits related to federal and state tax provisions.

Effective January 1, 2024, many jurisdictions implemented the Pillar Two rules issued by the Organization for Economic Co-operation and Development. In general, large multinational entity groups with consolidated revenue in excess of 750 million Euros in at least two of the preceding four years could be subject to the new rules in jurisdictions with an effective tax rate below fifteen percent. The Company currently does not operate in any jurisdictions that have implemented the Pillar Two rules, but jurisdictions may adopt retroactively to January 1, 2024. The Company does not expect the adoption of the Pillar Two rules by any jurisdiction in which it currently operates to have a material impact on its financial statements.

The tax years 2012 through 2023 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax.

15. RELATED PARTY TRANSACTIONS

The Company has entered into an arrangement for digital marketing services provided by a firm that is related to Mr. Kevin C. Clark, the Company's non-executive Chairman of the Board of Directors since April 1, 2022, and the Company's Co-Founder & Chief Executive Officer through March 31, 2022. Mr. Clark is a minority shareholder in the firm's parent company and is a member of the parent company's Board of Directors. Management believes that the terms of the arrangement are equivalent to those prevailing in an arm's-length transaction and have been approved by the Audit Committee of the Company's Board of Directors through the Company's related party transaction approval process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three and six months ended June 30, 2024 and 2023, the Company incurred an immaterial amount in expenses and had an immaterial payable balance at June 30, 2024 and December 31, 2023.

The Company provides services to entities which are affiliated with certain members of the Company's Board of Directors. Management believes that the services were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was immaterial for the three and six months ended June 30, 2024 and 2023. Accounts receivable due from these entities was an immaterial amount at June 30, 2024 and December 31, 2023.

16. SUBSEQUENT EVENT

On July 29, 2024, the Company amended its Loan Agreement. The amendment allows for all share repurchases paid in cash prior to June 30, 2024 and thereafter to be excluded as restricted payments in the fixed charge coverage ratio calculation, if as of the date of the share repurchase, there is no revolving ABL balance (except for interest and fees payable in accordance with the terms of the Loan Agreement).

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The purpose of the following Management's Discussion and Analysis (MD&A) is to help facilitate the understanding of significant factors influencing the quarterly operating results, financial condition, and cash flows of the Company. Additionally, MD&A also conveys our current expectations of the potential impact of known trends, events, or uncertainties that may impact future results. MD&A is provided as a supplement to, and should be read in conjunction with, our Annual Report on Form 10-K for the year ended December 31, 2023 (2023 Form 10-K) (including Part I, Item 1A. "Risk Factors"), our financial statements and the accompanying notes to our financial statements.

Business Overview

We provide total talent management services, including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers across the continuum of care, by recruiting and placing highly qualified healthcare professionals in virtually every specialty and area of expertise. In addition to clinical roles such as school nurses, speech language, and behavioral therapists, we place non-clinical professionals such as teachers, substitute teachers, and other education specialties at educational facilities across the nation. Our diverse customer base includes both public and private acute care and non-acute care hospitals, outpatient clinics, ambulatory care facilities, single- and multi-specialty physician practices, rehabilitation facilities, Program of All-Inclusive Care for the Elderly (PACE) programs, urgent care centers, local and national healthcare systems, managed care providers, public and charter schools, correctional facilities, government facilities, pharmacies, and many other healthcare providers. Through our national staffing teams, we offer our workforce solutions and place clinicians on travel and per diem assignments, local short-term contracts, and permanent positions. In addition, we continually evaluate opportunities to acquire companies that would complement or enhance our business, like WSG and Mint.

Our workforce solutions include managed service programs (MSPs), vendor management systems (VMS), in-home care services, education health services, recruitment process outsourcing (RPO), project management, and other outsourcing and consultative services as described in Item 1. "Business" in our 2023 Form 10-K. By utilizing the solutions that we offer, customers are able to better plan their personnel needs, optimize their talent acquisition and management processes, strategically flex and balance their workforce, have access to quality healthcare personnel, and provide continuity of care for improved patient outcomes. We have a history of investing in diversity, equality, and inclusion as a key component of the organization's overall corporate social responsibility program, which we believe is closely aligned with our core values to create a better future for our people, communities, and our stockholders.

The Company's two reportable segments offer services to its customers as described below:

- *Nurse and Allied Staffing* – Nurse and Allied Staffing represented approximately 86% of total revenue in the second quarter of 2024. The Nurse and Allied Staffing segment provides workforce solutions and traditional staffing, including temporary and permanent placement of travel nurses and allied professionals, as well as per diem and contract nurses and allied personnel. We also provide clinical and non-clinical professionals on short-term and long-term assignments to customers such as local and national healthcare plans, managed care providers, public and charter schools, correctional facilities, skilled nursing facilities, and other non-acute settings. In addition, Nurse and Allied Staffing provides executive search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. We provide flexible workforce solutions to our healthcare customers through diversified offerings designed to meet their unique needs, including MSP, RPO, and consulting services. We also offer our SaaS-based, proprietary, vendor management technology, Intellify[®] to facilities to manage all or a portion of their agency services.

- *Physician Staffing* – Physician Staffing represented approximately 14% of total revenue in the second quarter of 2024. Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States.

Summary of Operations

For the quarter ended June 30, 2024, revenue from services decreased 37% year-over-year to \$339.8 million, due to a 26% decrease in demand and a 21% decrease in average bill rates within the Nurse and Allied Staffing segment, primarily in travel nursing, while Homecare Staffing experienced 12% year-over-year revenue growth and 6% sequential revenue growth. The Physician Staffing segment experienced 7% year-over-year and 3% sequential revenue growth due to a price increase of 12% and a volume increase of 2%. Net loss attributable to common stockholders in the second quarter of 2024 was \$16.1 million, as compared to net income of \$21.3 million for the same period in the prior year.

For the three months ended June 30, 2024, cash and cash equivalents totaled \$69.6 million, with no debt outstanding. Cash flow provided by operating activities for the six months ended June 30, 2024 was \$88.4 million, with a decrease in working capital stemming from a decrease in net receivables, partially offset by the timing of disbursements. As of June 30, 2024, there were no borrowings drawn under the revolving senior-secured asset-based credit facility (ABL), and borrowing base availability was \$166.7 million, with \$152.9 million of availability net of \$13.8 million of letters of credit.

We have been able to execute in the challenging travel staffing environment, with a positive demand trajectory as we exited the quarter. Our technology initiatives are enhancing our competitive positioning, driven in part by Intellify[®]'s traction in the marketplace. Over 90% of our existing travel customers have transitioned to Intellify[®]. We will remain responsive to the current market conditions while also ensuring that we maintain a solid foundation for growth.

See Results of Operations, Segment Results, and Liquidity and Capital Resources sections that follow for further information.

Operating Metrics

We evaluate our financial condition by tracking operating metrics and financial results specific to each of our segments. Key operating metrics include hours worked, days filled, number of contract personnel on a full-time equivalent (FTE) basis, revenue per FTE, and revenue per day filled. Other operating metrics include number of open orders, candidate applications, contract bookings, length of assignment, bill and pay rates, renewal and fill rates, number of active searches, and number of placements. These operating metrics are representative of trends that assist management in evaluating business performance. Due to the timing of our business process and other factors, certain of these operating metrics may not necessarily correlate to the reported U.S. GAAP results for the periods presented. Some of the segment financial results analyzed include revenue, operating expenses, and contribution income. In addition, we monitor cash flow, as well as operating and leverage ratios, to help us assess our liquidity needs.

Business Segment	Business Measurement
Nurse and Allied Staffing	FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis. Average revenue per FTE per day is calculated by dividing the Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.
Physician Staffing	Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by eight hours. Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

Results of Operations

The following table summarizes, for the periods indicated, selected condensed consolidated statements of operations and comprehensive (loss) income data expressed as a percentage of revenue. Our historical results of operations are not necessarily indicative of future operating results.

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2024	2023	2024	2023
Revenue from services	100.0 %	100.0 %	100.0 %	100.0 %
Direct operating expenses	79.2	77.2	79.4	77.5
Selling, general and administrative expenses	17.7	14.6	17.2	14.0
Credit loss expense	5.6	0.6	2.8	0.7
Depreciation and amortization	1.4	0.8	1.3	0.8
Restructuring costs	0.6	0.2	0.4	0.1
Legal and other losses	1.2	—	1.1	0.1
Impairment charges	—	0.1	0.1	—
(Loss) income from operations	(5.7)	6.5	(2.3)	6.8
Interest expense	0.2	0.6	0.1	0.6
Loss on early extinguishment of debt	—	0.3	—	0.1
Other (income) expense, net	(0.1)	—	(0.2)	—
(Loss) income before income taxes	(5.8)	5.6	(2.2)	6.1
Income tax (benefit) expense	(1.1)	1.7	(0.3)	1.7
Net (loss) income attributable to common stockholders	(4.7)%	3.9 %	(1.9)%	4.4 %

Comparison of Results for the Three Months Ended June 30, 2024 and the Three Months Ended June 30, 2023

	Three Months Ended June 30,			
	2024	2023	Increase (Decrease) \$	Increase (Decrease) %
	(Amounts in thousands)			
Revenue from services	\$ 339,771	\$ 540,695	\$ (200,924)	(37.2)%
Direct operating expenses	268,966	417,556	(148,590)	(35.6)%
Selling, general and administrative expenses	60,258	78,938	(18,680)	(23.7)%
Credit loss expense	18,858	3,134	15,724	501.7 %
Depreciation and amortization	4,719	4,432	287	6.5 %
Restructuring costs	2,116	913	1,203	131.8 %
Legal and other losses	3,946	—	3,946	100.0 %
Impairment charges	114	533	(419)	(78.6)%
(Loss) income from operations	(19,206)	35,189	(54,395)	(154.6)%
Interest expense	568	3,149	(2,581)	(82.0)%
Loss on early extinguishment of debt	—	1,723	(1,723)	(100.0)%
Other (income) expense, net	(212)	11	(223)	NM
(Loss) income before income taxes	(19,562)	30,306	(49,868)	(164.5)%
Income tax (benefit) expense	(3,512)	8,961	(12,473)	(139.2)%
Net (loss) income attributable to common stockholders	\$ (16,050)	\$ 21,345	\$ (37,395)	(175.2)%

NM - Not meaningful

Revenue from services

Revenue from services decreased 37.2% to \$339.8 million for the three months ended June 30, 2024, as compared to \$540.7 million for the three months ended June 30, 2023, due to volume and bill rate declines in the Nurse and Allied Staffing segment partially offset by volume and price increases in the Physician Staffing segment. See further discussion in Segment Results.

Direct operating expenses

Direct operating expenses consist primarily of field employee compensation and independent contractor expenses, housing expenses, travel expenses, and related insurance expenses. Direct operating expenses decreased \$148.6 million, or 35.6%, to \$269.0 million for the three months ended June 30, 2024, as compared to \$417.6 million for the three months ended June 30, 2023, as a result of revenue decreases and the tightening of the bill/pay spreads. As a percentage of total revenue, direct operating expenses increased to 79.2%, as compared to 77.2% in the prior year period.

Selling, general and administrative expenses

Selling, general and administrative expenses decreased 23.7% to \$60.3 million for the three months ended June 30, 2024, as compared to \$78.9 million for the three months ended June 30, 2023, primarily due to decreases in compensation and benefit expense through proactive cost management. As a percentage of total revenue, selling, general and administrative expenses increased to 17.7% for the three months ended June 30, 2024, as compared to 14.6% for the three months ended June 30, 2023.

Credit loss expense

Credit loss expense for the three months ended June 30, 2024 was \$18.9 million, as compared to \$3.1 million for the three months ended June 30, 2023. The increase was driven by a bankruptcy filing by a single large customer. There is no significant impact on operations from this client as the majority of the business had been wound down in the prior year. As a percentage of revenue, credit loss expense was 5.6% for the three months ended June 30, 2024, as compared to 0.6% for the three months ended June 30, 2023.

Depreciation and amortization expense

Depreciation and amortization expense for the three months ended June 30, 2024 was \$4.7 million, as compared to \$4.4 million for the three months ended June 30, 2023. As a percentage of revenue, depreciation and amortization expense was 1.4% for the three months ended June 30, 2024 and 0.8% for the three months ended June 30, 2023.

Restructuring costs

Restructuring costs for the three months ended June 30, 2024 and 2023 were primarily comprised of employee termination costs. See Note 2 - Summary of Significant Accounting Policies to our condensed consolidated financial statements.

Legal and other losses

During the second quarter of 2024, the Company recorded legal and other losses of \$3.9 million which included the settlement of a class action lawsuit, as well as costs related to an unrecoverable asset. There were no such charges for the three months ended June 30, 2023.

Impairment charges

Non-cash impairment charges for the three months ended June 30, 2024 related to real estate restructuring activities. Non-cash impairment charges for the three months ended June 30, 2023 related to the write-off of an abandoned IT project.

Interest expense

Interest expense was \$0.6 million for the three months ended June 30, 2024, as compared to \$3.1 million for the three months ended June 30, 2023, due to lower average borrowings, partially offset by a higher effective interest rate.

Loss on early extinguishment of debt

Loss on early extinguishment of debt for the three months ended June 30, 2023 consisted of the write-off of debt issuance costs related to the repayment and termination of our term loan in the second quarter of 2023. There were no such charges for the three months ended June 30, 2024.

Income tax (benefit) expense

Income tax benefit totaled \$3.5 million for the three months ended June 30, 2024, as compared to expense of \$9.0 million for the three months ended June 30, 2023. The decrease in income tax expense was related to a decrease in book income primarily driven by credit loss expense as discussed in Note 2 - Summary of Significant Accounting Policies to our condensed consolidated financial statements. The tax amounts for the three months ended June 30, 2024 and 2023 were impacted by federal and state taxes. See Note 14 - Income Taxes to our condensed consolidated financial statements.

Comparison of Results for the Six Months Ended June 30, 2024 and the Six Months Ended June 30, 2023

	Six Months Ended June 30,			
	2024	2023	Increase (Decrease) \$	Increase (Decrease) %
	(Amounts in thousands)			
Revenue from services	\$ 718,945	\$ 1,163,402	\$ (444,457)	(38.2)%
Direct operating expenses	570,843	900,840	(329,997)	(36.6)%
Selling, general and administrative expenses	123,510	163,198	(39,688)	(24.3)%
Credit loss expense	20,148	8,042	12,106	150.5 %
Depreciation and amortization	9,361	9,336	25	0.3 %
Restructuring costs	3,054	1,342	1,712	127.6 %
Legal and other losses	7,596	1,125	6,471	575.2 %
Impairment charges	718	533	185	34.7 %
(Loss) income from operations	(16,285)	78,986	(95,271)	(120.6)%
Interest expense	1,030	6,839	(5,809)	(84.9)%
Loss on early extinguishment of debt	—	1,723	(1,723)	(100.0)%
Other income, net	(1,442)	(1)	(1,441)	NM
(Loss) income before income taxes	(15,873)	70,425	(86,298)	(122.5)%
Income tax (benefit) expense	(2,515)	19,644	(22,159)	(112.8)%
Net (loss) income attributable to common stockholders	<u>\$ (13,358)</u>	<u>\$ 50,781</u>	<u>\$ (64,139)</u>	<u>(126.3)%</u>

NM - Not meaningful

Revenue from services

Revenue from services decreased 38.2% to \$718.9 million for the six months ended June 30, 2024, as compared to \$1.2 billion for the six months ended June 30, 2023, due to volume and bill rate declines in the Nurse and Allied Staffing segment, partially offset by volume and price increases in the Physician Staffing segment. See further discussion in Segment Results.

Direct operating expenses

Direct operating expenses decreased \$330.0 million, or 36.6%, to \$570.8 million for the six months ended June 30, 2024, as compared to \$900.8 million for the six months ended June 30, 2023, as a result of revenue decreases and the tightening of bill/pay spreads. As a percentage of total revenue, direct operating expenses increased to 79.4%, as compared to 77.5% in the prior year period.

Selling, general and administrative expenses

Selling, general and administrative expenses decreased 24.3% to \$123.5 million for the six months ended June 30, 2024, as compared to \$163.2 million for the six months ended June 30, 2023, primarily due to decreases in compensation and benefit expense through proactive cost management, as well as a decrease in marketing expense. As a percentage of total revenue, selling, general and administrative expenses increased to 17.2% for the six months ended June 30, 2024, as compared to 14.0% for the six months ended June 30, 2023.

Credit loss expense

Credit loss expense for the six months ended June 30, 2024 was \$20.1 million, as compared to \$8.0 million for the six months ended June 30, 2023. The increase was driven by a bankruptcy filing by a single large customer. There is no significant impact on operations from this client as the majority of the business had been wound down in the prior year. As a percentage of revenue, credit loss expense was 2.8% for the six months ended June 30, 2024, as compared to 0.7% for the six months ended June 30, 2023.

Depreciation and amortization expense

Depreciation and amortization expense for the six months ended June 30, 2024 was \$9.4 million, as compared to \$9.3 million for the six months ended June 30, 2023. As a percentage of revenue, depreciation and amortization expense was 1.3% for the six months ended June 30, 2024 and 0.8% for the six months ended June 30, 2023.

Restructuring costs

Restructuring costs for the six months ended June 30, 2024 were primarily comprised of employee termination costs and ongoing lease exit costs. Restructuring costs for the six months ended June 30, 2023 were primarily comprised of employee termination costs, partially offset by an immaterial lease-related benefit. See Note 2 - Summary of Significant Accounting Policies to our condensed consolidated financial statements.

Legal and other losses

During the six months ended June 30, 2024, the Company recorded legal and other losses of \$7.6 million which included the settlement of a class action lawsuit, as well as costs related to an unrecoverable asset. Legal and other losses totaled \$1.1 million for the six months ended June 30, 2023 and related to the settlement of a wage and hour class action lawsuit and associated legal fees.

Impairment charges

Non-cash impairment charges for the six months ended June 30, 2024 related to real estate restructuring activities. Non-cash impairment charges for the six months ended June 30, 2023 related to the write-off of an abandoned IT project.

Interest expense

Interest expense was \$1.0 million for the six months ended June 30, 2024, as compared to \$6.8 million for the six months ended June 30, 2023, due to lower average borrowings, partially offset by a higher effective interest rate.

Loss on early extinguishment of debt

Loss on early extinguishment of debt for the six months ended June 30, 2023 consisted of the write-off of debt issuance costs related to the repayment and termination of our term loan in the second quarter of 2023. There were no such charges for the six months ended June 30, 2024.

Other income, net

For the six months ended June 30, 2024, other income, net included a \$0.9 million decrease of the remaining earnout liability related to the Mint acquisition. See Note 4 - Acquisitions to our condensed consolidated financial statements.

Income tax (benefit) expense

Income tax benefit totaled \$2.5 million for the six months ended June 30, 2024, as compared to expense of \$19.6 million for the six months ended June 30, 2023. The decrease in income tax expense was related to a decrease in book income primarily driven by credit loss expense as discussed in Note 2 - Summary of Significant Accounting Policies to our condensed consolidated financial statements. The tax amounts for the six months ended June 30, 2024 and 2023 were impacted by federal and state taxes. See Note 14 - Income Taxes to our condensed consolidated financial statements.

Segment Results

Information on operating segments and a reconciliation to (loss) income from operations for the periods indicated are as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
(amounts in thousands)				
Revenue from services:				
Nurse and Allied Staffing	\$ 291,451	\$ 495,376	\$ 623,637	\$ 1,077,678
Physician Staffing	48,320	45,319	95,308	85,724
	<u>\$ 339,771</u>	<u>\$ 540,695</u>	<u>\$ 718,945</u>	<u>\$ 1,163,402</u>
Contribution income:				
Nurse and Allied Staffing	\$ 5,820	\$ 56,481	\$ 33,003	\$ 123,650
Physician Staffing	4,033	3,541	7,171	5,265
	<u>9,853</u>	<u>60,022</u>	<u>40,174</u>	<u>128,915</u>
Corporate overhead	18,161	18,891	35,727	37,547
Depreciation and amortization	4,719	4,432	9,361	9,336
Restructuring costs	2,116	913	3,054	1,342
Legal and other losses	3,946	—	7,596	1,125
Impairment charges	114	533	718	533
Other costs	3	64	3	46
(Loss) income from operations	<u>\$ (19,206)</u>	<u>\$ 35,189</u>	<u>\$ (16,285)</u>	<u>\$ 78,986</u>

See Note 12 - Segment Data to our condensed consolidated financial statements.

Certain statistical data for our business segments for the periods indicated are as follows:

	Three Months Ended		Change	Percent Change
	June 30, 2024	June 30, 2023		
<u>Nurse and Allied Staffing statistical data:</u>				
FTEs	8,415	11,385	(2,970)	(26.1)%
Average Nurse and Allied Staffing revenue per FTE per day	\$ 377	\$ 474	\$ (97)	(20.5)%

<u>Physician Staffing statistical data:</u>				
Days filled	24,252	23,826	426	1.8 %
Revenue per day filled	\$ 1,992	\$ 1,902	\$ 90	4.7 %

	Six Months Ended		Change	Percent Change
	June 30, 2024	June 30, 2023		
<u>Nurse and Allied Staffing statistical data:</u>				
FTEs	8,770	11,952	(3,182)	(26.6)%
Average Nurse and Allied Staffing revenue per FTE per day	\$ 388	\$ 494	\$ (106)	(21.5)%

<u>Physician Staffing statistical data:</u>				
Days filled	48,037	45,923	2,114	4.6 %
Revenue per day filled	\$ 1,984	\$ 1,867	\$ 117	6.3 %

See definition of Business Measurements under the Operating Metrics section of the MD&A.

Segment Comparison - Three Months Ended June 30, 2024 and Three Months Ended June 30, 2023

Nurse and Allied Staffing

Revenue decreased \$203.9 million, or 41.2%, to \$291.5 million for the three months ended June 30, 2024, as compared to \$495.4 million for the three months ended June 30, 2023, driven primarily by a 26% decline in billable hours and, to a lesser extent, a 21% normalization in bill rates. Within the segment, HomeCare Staffing experienced year-over-year revenue growth of 12.0% and sequential revenue growth of 5.5% in the second quarter of 2024.

Contribution income decreased \$50.7 million, or 89.7%, to \$5.8 million for the three months ended June 30, 2024, as compared to \$56.5 million for the three months ended June 30, 2023. As a percentage of segment revenue, contribution income margin was 2.0% for the three months ended June 30, 2024, as compared to 11.4% for the three months ended June 30, 2023.

The average number of FTEs on contract during the three months ended June 30, 2024 decreased 26.1% from the three months ended June 30, 2023, primarily due to headcount decline in travel nurse and per diem. The average revenue per FTE per day decreased 20.5%.

Physician Staffing

Revenue increased \$3.0 million, or 6.6%, to \$48.3 million for the three months ended June 30, 2024, as compared to \$45.3 million for the three months ended June 30, 2023, primarily due to a 2% increase in billable days, as well as price increases of 12%.

Contribution income was \$4.0 million for the three months ended June 30, 2024, as compared to \$3.5 million for the three months ended June 30, 2023. As a percentage of segment revenue, contribution income was 8.3% for the three months ended June 30, 2024, as compared to 7.8% for the three months ended June 30, 2023.

Total days filled for the three months ended June 30, 2024 was 24,252, as compared with 23,826 in the prior year. Revenue per day filled was \$1,992 as compared with \$1,902 in the prior year, due to price increases.

Corporate Overhead

Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs, such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects. Corporate overhead decreased to \$18.2 million for the three months ended June 30, 2024, from \$18.9 million for the three months ended June 30, 2023, primarily due to decreases in compensation and benefit expense, and professional fees, partially offset by increases in insurance and taxes. As a percentage of consolidated revenue, corporate overhead was 5.3% for the three months ended June 30, 2024 and 3.5% for the three months ended June 30, 2023.

Segment Comparison - Six Months Ended June 30, 2024 and Six Months Ended June 30, 2023

Nurse and Allied Staffing

Revenue decreased \$454.0 million, or 42.1%, to \$623.6 million for the six months ended June 30, 2024, as compared to \$1.1 billion for the six months ended June 30, 2023, driven primarily by a 26% decline in billable hours and, to a lesser extent, a 22% normalization in bill rates. Within the segment, HomeCare Staffing experienced year-over-year revenue growth of 7.5% for the six months ended June 30, 2024.

Contribution income decreased \$90.7 million, or 73.3%, to \$33.0 million for the six months ended June 30, 2024, as compared to \$123.7 million for the six months ended June 30, 2023. As a percentage of segment revenue, contribution income margin was 5.3% for the six months ended June 30, 2024, as compared to 11.5% for the six months ended June 30, 2023.

The average number of FTEs on contract during the six months ended June 30, 2024 decreased 26.6% from the six months ended June 30, 2023, primarily due to headcount decline in travel nurse and allied, and per diem. The average revenue per FTE per day decreased 21.5%.

Physician Staffing

Revenue increased \$9.6 million, or 11.2%, to \$95.3 million for the six months ended June 30, 2024, as compared to \$85.7 million for the six months ended June 30, 2023, primarily due to a 5% increase in billable days, as well as price increases of 15%.

Contribution income was \$7.2 million for the six months ended June 30, 2024, as compared to \$5.3 million for the six months ended June 30, 2023. As a percentage of segment revenue, contribution income was 7.5% for the six months ended June 30, 2024, as compared to 6.1% for the six months ended June 30, 2023.

Total days filled for the six months ended June 30, 2024 was 48,037, as compared with 45,923 in the prior year. Revenue per day filled was \$1,984 as compared with \$1,867 in the prior year, due to price increases.

Corporate Overhead

Corporate overhead decreased to \$35.7 million for the six months ended June 30, 2024, from \$37.5 million for the six months ended June 30, 2023, primarily due to decreases in compensation and benefit expense, and professional fees, partially offset by increases in computer expenses, insurance, and workers' compensation. As a percentage of consolidated revenue, corporate overhead was 5.0% for the six months ended June 30, 2024 and 3.2% for the six months ended June 30, 2023.

Liquidity and Capital Resources

On June 30, 2023, we repaid all \$73.9 million in outstanding obligations under the term loan and terminated the Term Loan Agreement (as defined below). As of June 30, 2024, we reported \$69.6 million in cash and cash equivalents, with no borrowings drawn under the ABL, and no off-balance sheet arrangements. Working capital decreased by \$39.0 million to \$227.6 million as of June 30, 2024, as compared to \$266.6 million as of December 31, 2023, primarily due to a decrease in net receivables, partially offset by the timing of disbursements. As of June 30, 2024, our days' sales outstanding, net of amounts owed to subcontractors, was 56 days, down 7 days year-over-year and down 18 days sequentially.

Operating cash flow constitutes our primary source of liquidity and, historically, has been sufficient to fund working capital, capital expenditures, internal business expansion, and debt service. This includes commitments, both short-term and long-term, of interest expense on our debt and operating lease commitments, and future principal payments on the ABL. We expect to

meet our future cash needs from a combination of cash on hand, operating cash flows, and funds available through the ABL. See the debt discussion which follows.

As of May 2023, the Company maintains a \$100.0 million Board-authorized stock repurchase program (Repurchase Program). In the third quarter of 2023, the Company entered into a Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company's blackout periods, beginning on January 2, 2024 through November 7, 2024. During the six months ended June 30, 2024, the Company repurchased a total of 1,290,156 shares of common stock for \$21.3 million, at an average price of \$16.50 per share. As of June 30, 2024, we had \$56.0 million remaining for share repurchase under the Repurchase Program, subject to certain conditions in our Loan Agreement (as defined below).

Net cash provided by operating activities decreased \$77.7 million to \$88.4 million for the six months ended June 30, 2024, as compared to \$166.1 million for the six months ended June 30, 2023.

Net cash used in investing activities was \$5.1 million for the six months ended June 30, 2024, as compared to \$7.5 million for the six months ended June 30, 2023. Net cash used in the six months ended June 30, 2024 was for capital expenditures. Net cash used in the six months ended June 30, 2023 was for capital expenditures and an immaterial amount related to a local business acquisition.

Net cash used in financing activities during the six months ended June 30, 2024 was \$30.8 million, as compared to \$161.6 million during the six months ended June 30, 2023. During the six months ended June 30, 2024, we used cash to pay \$2.9 million for income taxes on share-based compensation, \$21.3 million for share repurchases, and \$6.6 million for contingent consideration. During the six months ended June 30, 2023, we reported net repayments of \$119.7 million on debt, and used cash to pay \$4.9 million for income taxes on share-based compensation, \$36.5 million for share repurchases, and an immaterial amount for other financing activities.

Debt

2021 Term Loan Credit Agreement

On June 8, 2021, we entered into the Term Loan Credit Agreement (Term Loan Agreement), which provided for a six-year second lien subordinated term loan in the amount of \$100.0 million (term loan). On November 18, 2021, we amended the Term Loan Agreement (Term Loan First Amendment), which provided the Company an incremental term loan in an aggregate amount equal to \$75.0 million. On April 14, 2023, we amended the Term Loan Agreement (Term Loan Second Amendment), which provided the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or the Base Rate (as defined in the Term Loan Agreement), at the election of the borrowers, plus an applicable margin. With respect to any SOFR loan, the rate per annum was equal to the Term SOFR (as defined in the Term Loan Second Amendment) for the interest period plus an adjustment of 10 basis points due to the credit spread associated with the transition to SOFR.

As more fully described in Note 8 - Debt to our condensed consolidated financial statements, on June 30, 2023, we repaid all outstanding obligations under the term loan, and terminated the Term Loan Agreement. As a result, debt issuance costs of \$1.7 million were written off in the second quarter of 2023 and are included as loss on early extinguishment of debt in the condensed consolidated statements of operations and comprehensive (loss) income. All subsidiary guarantees of the term loan were automatically released upon the termination of the Term Loan Agreement.

2019 Asset-Based Loan Agreement

Effective October 25, 2019, the prior senior credit facility entered into in August 2017 was replaced by a \$120.0 million asset-based loan agreement (Loan Agreement), which provided for a five-year senior secured revolving credit facility. On June 30, 2020, we amended the Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from \$120.0 million to \$130.0 million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. On March 8, 2021, we amended the Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from \$130.0 million to \$150.0 million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers. On June 8, 2021, we amended the Loan Agreement (Third Amendment), which permitted the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement, and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars. On November 18, 2021, we amended the Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined

in the Loan Agreement) was increased to \$175.0 million. On March 21, 2022, we amended the Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from \$150.0 million to \$300.0 million, extended the credit facility for an additional five years, increased certain borrowing base sub-limits, and provided the option for all or a portion of the borrowings to bear interest at a rate based on SOFR or Base Rate (as defined in the Loan Agreement), at the election of the borrowers, plus an applicable margin. On September 29, 2023, we amended the Loan Agreement (Sixth Amendment), which changed the minimum fixed charge coverage ratio from a maintenance covenant to a springing covenant based on excess availability. For the three months ended June 30, 2024, the excess availability did not fall below the stated threshold and, as a result, there was no covenant compliance period.

As of June 30, 2024, the interest rate spreads and fees under the ABL were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate margin would have been 0.75% for the revolving portion. The SOFR and Base Rate margins are subject to monthly adjustments, pursuant to a pricing matrix based on our excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. Borrowing base availability under the ABL was \$166.7 million as of June 30, 2024, with no borrowings drawn and \$152.9 million of availability net of \$13.8 million of letters of credit.

See Note 8 - Debt to our condensed consolidated financial statements.

Critical Accounting Policies and Estimates

Our critical accounting policies and estimates remain consistent with those reported in our 2023 Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

We are exposed to variable interest rate risk associated with our Loan Agreement entered into on October 25, 2019. This agreement charges interest at a rate based on either SOFR or Base Rate (as defined in the Loan Agreement) plus an applicable margin. Our Term Loan Agreement, entered into on June 8, 2021, was repaid and terminated on June 30, 2023.

A 1.0% change in interest rates would have resulted in interest expense fluctuating an immaterial amount for the six months ended June 30, 2024 and 2023, respectively. See Note 8 - Debt to our condensed consolidated financial statements.

Other Risks

There have been no material changes to our other exposures as disclosed in our 2023 Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this report. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective. Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, communicated to management, including the Chief Executive Officer and the Chief Financial Officer, and reported within the time periods specified in the SEC’s rules and forms. The disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports required under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, in order to allow timely decisions regarding any required disclosure.

During the second quarter of 2024, we implemented a new company-wide enterprise resource planning (ERP) system. We have appropriately considered this change in our design and testing for effectiveness of internal controls and concluded that, as part of the evaluation described above, the ERP implementation has not materially affected our internal control over financial reporting.

There were no other changes in our internal control over financial reporting as defined in Exchange Act Rules 13a-15(f) that occurred during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Information with respect to certain legal proceedings is included in Part I, Item 1, Note 13 - Contingencies - *Legal Proceedings* of this Quarterly Report on Form 10-Q, and is incorporated herein by reference.

ITEM 1A. RISK FACTORS

There are no material changes to our Risk Factors as previously disclosed in our 2023 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(c) Issuer Purchases of Equity Securities

The following table sets forth the number of shares purchased, the average price paid per share, the total number of shares purchased as part of publicly announced programs, and the approximate dollar value of shares that may yet be purchased under the programs during each month in the second fiscal quarter ended June 30, 2024. See Note 11 - Stockholders' Equity contained in "Notes to Condensed Consolidated Financial Statements" in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (a)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (b)
(dollar value in thousands, except per share data)				
April 1 through April 30	189,278	\$17.61	189,278	\$67,562
May 1 through May 31	259,921	\$14.92	259,921	\$63,684
June 1 through June 30	530,722	\$14.53	530,722	\$55,970
Total	979,921	\$15.23	979,921	\$55,970

(a) Shares were repurchased under the Repurchase Program. The Repurchase Program has no expiration date but may be terminated by the Board of Directors at any time. No shares were purchased other than through publicly announced programs during the periods shown.

(b) As of May 1, 2023, the Board of Directors has authorized an aggregate of \$100.0 million in share repurchases under the Repurchase Program. Amounts shown in this column reflect amounts remaining under the Repurchase Program referenced in Note 11 - Stockholders' Equity in Part I, Item 1 of this Quarterly Report on Form 10-Q.

ITEM 5. OTHER INFORMATION

(c) Trading Plans

Certain directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company may execute purchases and sales of the Company's common stock through Rule 10b5-1 and non-Rule 10b5-1 equity trading plans. Pursuant to Item 408(a) of Regulation S-K, we are required to disclose whether any director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as that term is defined in Item 408(c) of Regulation S-K) during the most recently completed quarter.

During the three months ended June 30, 2024, neither the Company nor any of its Section 16 officers or directors adopted, modified, or terminated any contract, instruction, or written plan for the purchase or sale of the Company's securities, under either a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K).

ITEM 6. EXHIBITS

No.	Description
3.1	<u>Amended and Restated By-laws of the Registrant (Previously filed as an exhibit to the Company's Form 10-Q for the quarter ended March 31, 2024 and incorporated by reference herein.)</u>
10.1	<u>Amendment No. 7 to ABL Credit Agreement, dated as of July 29, 2024, by and among Cross Country Healthcare, Inc. and certain of its domestic subsidiaries as borrowers or guarantors, and Wells Fargo Bank, N.A., as administrative agent, collateral agent, and lender (Previously filed as an exhibit to the Company's Form 8-K dated July 29, 2024 and incorporated by reference herein.)</u>
*31.1	<u>Certification pursuant to Rule 13a-14(a) and Rule 15d-14(a) and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by John A. Martins, President, Chief Executive Officer, Director (Principal Executive Officer)</u>
*31.2	<u>Certification pursuant to Rule 13a-14(a) and Rule 15d-14(a) and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by William J. Burns, Executive Vice President, Chief Financial Officer (Principal Financial Officer)</u>
**32.1	<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by John A. Martins, President, Chief Executive Officer, Director (Principal Executive Officer)</u>
**32.2	<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by William J. Burns, Executive Vice President, Chief Financial Officer (Principal Financial Officer)</u>
*101.INS	XBRL Instance Document
*101.SCH	XBRL Taxonomy Extension Schema Document
*101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
*101.LAB	XBRL Taxonomy Extension Label Linkbase Document
*101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
*101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
#	Represents a management contract or compensatory plan or arrangement
*	Filed herewith
**	Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 1, 2024

CROSS COUNTRY HEALTHCARE, INC.

By: /s/ William J. Burns

William J. Burns
Executive Vice President & Chief Financial Officer
(Principal Financial Officer)

Certification

I, John A. Martins, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cross Country Healthcare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2024

/s/ John A. Martins

John A. Martins
President & Chief Executive Officer
(Principal Executive Officer)

Certification

I, William J. Burns, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cross Country Healthcare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2024

/s/ William J. Burns

William J. Burns
Executive Vice President & Chief Financial Officer (Principal Financial Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of Cross Country Healthcare, Inc. (the Company) for the quarterly period ended June 30, 2024, (the "Periodic Report"), I, John A. Martins, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

- (1) the Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 1, 2024

/s/ John A. Martins

John A. Martins
President & Chief Executive Officer
(Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cross Country Healthcare, Inc. and will be retained by Cross Country Healthcare, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is provided solely for purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act of 2002.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of Cross Country Healthcare, Inc. (the "Company") for the quarterly period ended June 30, 2024, (the "Periodic Report"), I, William J. Burns, Executive Vice President and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

- (1) the Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 1, 2024

/s/ William J. Burns

William J. Burns

Executive Vice President & Chief Financial Officer (Principal Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cross Country Healthcare, Inc. and will be retained by Cross Country Healthcare, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is provided solely for purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act of 2002.